Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $403 Million
Apogee Therapeutics, a Nasdaq-listed clinical-stage biotech company, successfully closed its underwritten public offering, raising approximately $403 million. The offering included 5,750,000 shares sold at $70 each and full exercise of underwriters' options. Proceeds will support the company’s development of novel biologics targeting inflammatory a…